WallStSmart

DTE Energy Company 2021 Series E (DTG)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

VMET leads profitability with a 58.5% profit margin vs 0.0%. VMET earns a higher WallStSmart Score of 45/100 (D+).

DTG

Avoid

23

out of 100

Grade: F

Growth: 3.3Profit: 4.0Value: 5.0Quality: 5.0

VMET

Hold

45

out of 100

Grade: D+

Growth: 5.3Profit: 8.0Value: 4.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DTG0 strengths · Avg: 0/10

No standout strengths identified

VMET3 strengths · Avg: 10.0/10
Profit MarginProfitability
58.5%10/10

Keeps 59 of every $100 in revenue as profit

Operating MarginProfitability
135.6%10/10

Strong operational efficiency at 135.6%

Revenue GrowthGrowth
465.2%10/10

Revenue surging 465.2% year-over-year

Areas to Watch

DTG4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

VMET3 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.29B3/10

Smaller company, higher risk/reward

P/E RatioValuation
56.6x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : DTG

DTG has a balanced fundamental profile.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.5% and operating margin at 135.6%. Revenue growth of 465.2% demonstrates continued momentum.

Bear Case : DTG

The primary concerns for DTG are Revenue Growth, EPS Growth, Return on Equity.

Bear Case : VMET

The primary concerns for VMET are EPS Growth, Market Cap, P/E Ratio. A P/E of 56.6x leaves little room for execution misses.

Key Dynamics to Monitor

DTG profiles as a value stock while VMET is a growth play — different risk/reward profiles.

VMET is growing revenue faster at 465.2% — sustainability is the question.

Monitor NONE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VMET scores higher overall (45/100 vs 23/100), backed by strong 58.5% margins and 465.2% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DTE Energy Company 2021 Series E

NONE · NONE · USA

DTE Energy Company 2021 Series E represents a compelling investment opportunity in the regulated utility sector, emphasizing reliable energy delivery primarily in Michigan. As a subsidiary of DTE Energy, this series highlights a solid financial standing and a dedication to consistent dividend payouts, making it appealing to institutional investors who prioritize stability and lower risk. The company actively promotes sustainability and invests in innovative energy solutions, enhancing its competitive edge while responding to the increasing demand for environmentally friendly practices. Supported by strong infrastructure and a favorable regulatory landscape, DTE Energy is well-positioned to succeed in the evolving energy market.

Versamet Royalties Corporation Common Stock

NONE · NONE · USA

Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing novel therapeutics for serious and life-threatening diseases, particularly through its innovative drug development platform that leverages its proprietary metalloenzyme-based technology. The company aims to address unmet medical needs in areas such as fungal infections and oncology, positioning itself at the forefront of therapeutic innovation. Viamet's strategic partnerships and strong intellectual property portfolio underscore its commitment to advancing its pipeline while maximizing shareholder value. As it progresses through clinical development phases, VMET stands to play a significant role in transforming treatment paradigms within its targeted therapeutic areas.

Want to dig deeper into these stocks?